Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) traded up 0.7% during mid-day trading on Monday . The company traded as high as $1.40 and last traded at $1.39. 98,483 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 264,581 shares. The stock had previously closed at $1.38.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Piper Sandler cut their price target on shares of Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research report on Thursday, May 30th.

Milestone Pharmaceuticals Stock Up 0.7 %

The company has a fifty day moving average of $1.60 and a 200 day moving average of $1.72. The company has a quick ratio of 22.75, a current ratio of 22.75 and a debt-to-equity ratio of 1.27. The company has a market cap of $74.03 million, a P/E ratio of -1.11 and a beta of 1.73.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.05. On average, research analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. BNP Paribas Financial Markets boosted its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 177.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,900 shares of the company’s stock after buying an additional 10,800 shares during the quarter. BNP Paribas Financial Markets’ holdings in Milestone Pharmaceuticals were worth $30,000 at the end of the most recent quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.